New DICOM solutions can connect Q-Stress and Q-Tel cardiac rehab to healthcare information systems
BOTHELL, Wash., March 30 /PRNewswire-FirstCall/ -- Cardiac Science , a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today added DICOM connectivity to its Quinton Q-Stress cardiac stress testing system and Quinton Q-Tel cardiac rehabilitation system.
“With DICOM and HL7 technologies, Cardiac Science is prepared to serve the hospitals and physicians ready to take advantage of the Economic Stimulus Bill,” Director of Diagnostic Marketing for Cardiac Science Rene Mitchell said. “This is another critical step in our path to be the diagnostic connectivity leaders.”
The Quinton Q-Stress can now connect to hospital information systems (HIS) and electronic medical records (EMR) in the way that works best for each practice or hospital. Among its benefits,
First to offer DICOM connectivity to cardiac rehab segment
Cardiac Science is the first to offer DICOM connectivity to the cardiac rehabilitation segment. With the addition of DICOM and HL7 technology, Q-Tel now supports all the latest industry standards for connectivity.
“More cardiac rehab centers will connect their patient records to HIS systems. Our DICOM and HL7 connectivity options will make the move much easier,” Mitchell added.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
Forward Looking Statements
This press release contains forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation’s expectations regarding revenue and profit potential stemming from DICOM and HL7 capabilities. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation’s Annual Report on Form 10-K for the year ended December 31, 2008. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
LOGO: http://www.cardiacscience.com/images/main_logo.gif
CSCX-G
CONTACT: Mike Matysik, Senior Vice President and CFO of Cardiac Science
Corporation, +1-425-402-2009; or Doug Sherk or Jenifer Kirtland, Investor
Contact, +1-415-896-6820, or Christopher Gale, Media Contact,
+1-646-201-5431, or +1-203-570-4681, or cgale@evcgroup.com, all of EVC
Group Inc.
Web site: http://www.cardiacscience.com/
http://www.cardiacscience.com/images/main_logo.gif/
